N25.0

Renal osteodystrophy

Renal osteodystrophy refers to the spectrum of bone morphology alterations that occur in patients with Chronic Kidney Disease (CKD). It is the histological component of the broader clinical syndrome known as Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). The condition is characterized by a complex interplay of biochemical abnormalities including hyperphosphatemia, hypocalcemia, secondary hyperparathyroidism, and deficient activation of Vitamin D (calcitriol). These metabolic derangements lead to various skeletal patterns: high-turnover bone disease (osteitis fibrosa cystica), low-turnover bone disease (adynamic bone disease or osteomalacia), or mixed osteodystrophy. As renal function declines, the kidneys lose their ability to excrete phosphorus and synthesize 1,25-dihydroxyvitamin D, forcing the parathyroid glands to overcompensate, which ultimately results in the resorption of bone mineral to maintain systemic calcium homeostasis at the expense of skeletal integrity.

Clinical Symptoms

Chronic bone and joint pain
Skeletal deformities (e.g., bowing of legs in children)
Increased susceptibility to fragility fractures
Proximal muscle weakness
Stunted growth or renal rickets in pediatric patients
Soft tissue calcification
Pruritus (itching) due to calcium-phosphate crystal deposition
Loss of height due to vertebral compression
Waddling gait

Common Causes

Chronic Kidney Disease (CKD) stages 3-5
End-Stage Renal Disease (ESRD)
Secondary hyperparathyroidism
Reduced renal conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D
Hyperphosphatemia due to impaired renal excretion
Hypocalcemia
Chronic metabolic acidosis
Aluminum toxicity (historically associated with phosphate binders)

Documentation & Coding Tips

Explicitly Link Bone Pathology to Chronic Kidney Disease Status

Example: Patient with ESRD on hemodialysis presents with chronic hip pain and elevated parathyroid hormone levels at 750 pg/mL. Diagnosis: Renal osteodystrophy (N25.0) secondary to ESRD (N18.6) on maintenance hemodialysis (Z99.2). Bone biopsy previously indicated osteitis fibrosa cystica. The condition is persistent and managed with cinacalcet and sevelamer.

Billing Focus: Documentation must specify the causal relationship between the renal failure and the bone disorder to support N25.0. Laterality should be specified if skeletal pain or fractures are present.

Document Specific Mineral and Bone Abnormalities

Example: 62-year-old male with CKD Stage 4 (N18.4) exhibiting hyperphosphatemia and hypocalcemia. Clinical findings consistent with renal osteodystrophy (N25.0). Current phosphorus level 6.2 mg/dL; calcium level 8.1 mg/dL. Prescribed phosphorus binders to mitigate bone turnover risks.

Billing Focus: Inclusion of laboratory values (Calcium, Phosphorus, PTH) provides the clinical evidence required for the N25.0 diagnosis.

Distinguish Between Secondary Hyperparathyroidism and Renal Osteodystrophy

Example: Assessment: Renal osteodystrophy (N25.0) manifesting as adynamic bone disease. Patient also has secondary hyperparathyroidism of renal origin (N25.81). Recent DEXA scan shows significant T-score decline in lumbar spine consistent with renal-induced metabolic bone disease.

Billing Focus: N25.0 specifically covers the bone pathology, while N25.81 covers the parathyroid dysfunction; both should be coded if present and documented.

Include Impact on Daily Activities and Skeletal Integrity

Example: Patient reports limited mobility and chronic bone pain in lower extremities due to renal osteodystrophy (N25.0) complicating CKD Stage 5 (N18.5). No current pathological fracture noted, but high risk persists due to elevated alkaline phosphatase.

Billing Focus: Describing the functional impact justifies the medical necessity of evaluation and management (E/M) services and high-complexity decision making.

Specify Treatments to Support Ongoing Condition Management

Example: Follow-up for renal osteodystrophy (N25.0). Patient remains stable on Calcitriol 0.25 mcg daily and Calcium acetate 667 mg with meals. Phosphorus remains controlled at 4.5 mg/dL. Monitoring for potential development of calciphylaxis.

Billing Focus: Listing specific medications for the management of bone mineral metabolism supports the active status of the chronic condition.

Relevant CPT Codes

99214 - Office or other outpatient visit for the evaluation and management of an established patient
Standard level of care for managing patients with complex metabolic bone disease and multiple CKD complications.
99213 - Office or other outpatient visit for the evaluation and management of an established patient
Appropriate for stable renal osteodystrophy monitoring without acute changes in symptoms or labs.
90960 - End-stage renal disease related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits
The primary way renal osteodystrophy is monitored and treated in the ESRD population.
83970 - Parathyroid hormone (PTH)
PTH is the primary marker used to diagnose and guide treatment of renal osteodystrophy.
82310 - Calcium; total
Crucial for calculating the calcium-phosphorus product in osteodystrophy management.
84100 - Phosphorus inorganic (phosphate);
Hyperphosphatemia is the key driver of osteodystrophy; monitoring is mandatory.
77080 - Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton
Used to monitor the progression of bone loss in renal patients.
82306 - Vitamin D; 25 hydroxy, includes fraction(s), if performed
Vitamin D deficiency is a major component of the development of N25.0.
99215 - Office or other outpatient visit for the evaluation and management of an established patient
Reserved for patients with severe complications like calciphylaxis or fractures complicating renal osteodystrophy.
20220 - Biopsy, bone, trocar, or needle; superficial
The gold standard for definitively characterizing the type of renal osteodystrophy (e.g., adynamic vs. hyperparathyroid).